INforMS – Page 31

People with MS may have trouble recognizing emotions -- MS can damage parts of the brain that allow us to recognize emotions in others. [...]

0

EMA validates marketing authorization application for ZINBRYTA for treatment of multiple sclerosis

INforMS, Partners

European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of [...]

0

Teva Neuroscience & Access Health team up for special multiple sclerosis awareness show: thursday, 3/5

INforMS, MS Community, Partners

Teva Neuroscience & Access Health Team Up for Special MS Awareness Show: Thursday, March 5 As Multiple Sclerosis Awareness Week [...]

0

Multiple sclerosis paroxysmal symptoms confused with seizures due to sudden onset

INforMS, MS Community

Multiple sclerosis paroxysmal symptoms can be confused with seizures due to its sudden onset. Paroxysmal symptoms are unique to multiple [...]

0

How Vitamin D repairs myelin in multiple sclerosis

INforMS, MS Community

An international team of researchers have proposed how vitamin D repairs myelin in multiple sclerosis. This finding could lead to [...]

0

Acorda announces data from first clinical trial of remyelinating antibody in multiple sclerosis

INforMS, Partners

Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis Phase 1 trial [...]

0

First multiple sclerosis patients in the U.S. receive Genzyme’s Lemtrada following FDA approval

INforMS, Partners

First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval – Lemtrada now available in the U.S. two weeks post [...]

0

Genzyme’s Lemtrada approved by the FDA

INforMS, Partners

Genzyme’s Lemtrada Approved by the FDA - Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows [...]

0

Genzyme announces enrollment of first patient in phase II Vatelizumab trial in RRMS

INforMS, MS Community, Partners

Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis Tuesday, November [...]

0

Results from two phase III studies added to U.S. label of Genzyme’s Aubagio

INforMS, Partners

Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio Once-daily Aubagio is the only oral treatment to [...]

Elizabeth Porco

15

0

Category Archives: "INforMS"

Recent Posts

Contact Us